drugset
drugset / Trial / NCT05791474

ATI-2231 in Advanced Solid Tumor Malignancies

NCT05791474 ↗

Phase 1 Withdrawn Washington University School of Medicine Aclaris Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

Timeline

Start
2023-11-15
Primary completion
2025-06-30
Completion
2025-06-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject ATI-2231 Unknown 20 mg Oral

Indications

high grade malignant neoplasm